• Home
  • NEW DAY MEDICINE
  • 6 (92) 2026
  • 64 -6 (92) 2026 - Kurbonova Z.Ch., Turobova M.Y., Eganberdiyev G’.M. - SUT BEZI SARATONIDA YANGI AVLOD SEKVENSLASH (NGS) TEKSHIRUVINING AFZALLIKLARI

64 -6 (92) 2026 - Kurbonova Z.Ch., Turobova M.Y., Eganberdiyev G’.M. - SUT BEZI SARATONIDA YANGI AVLOD SEKVENSLASH (NGS) TEKSHIRUVINING AFZALLIKLARI

SUT BEZI SARATONIDA YANGI AVLOD SEKVENSLASH (NGS) TEKSHIRUVINING AFZALLIKLARI

Kurbonova Z.Ch. - Toshkent Davlat Tibbiyot Universiteti

Turobova M.Y. - Toshkent Davlat Tibbiyot Universiteti

Eganberdiyev G’.M. - Respublika Onkologiya va Radiologiya Ilmiy-amaliy Tibbiyot Markazi Toshkent viloyati filiali

Rezyume

Ushbu adabiyotlar sharhida sut bezi saratoni diagnostikasi, prognozini baholash va davolashni individuallashtirishda yangi avlod sekvenslash (Next-Generation Sequencing, NGS) texnologiyasining o‘rni tahlil qilindi. NGS bir vaqtning o‘zida ko‘plab genetik o‘zgarishlarni aniqlash imkonini berib, o‘simtaning molekulyar xususiyatlarini chuqur o‘rganish, maqsadli terapiya uchun muhim biomarkerlarni aniqlash hamda irsiy saraton xavfini baholashga xizmat qiladi. Adabiyotlar tahlili NGS yordamida BRCA1, BRCA2, PIK3CA, TP53 va boshqa genlardagi mutatsiyalarni aniqlash davolash samaradorligini oshirish va bemorlar prognozini yaxshilashga yordam berishini ko‘rsatdi. Shuningdek, suyuq biopsiya bilan integratsiyalashgan NGS texnologiyasi kasallikning dinamik monitoringi, minimal qoldiq kasallikni erta aniqlash va davolashga rezistent klonlarni kuzatishda katta istiqbolga ega. NGSning klinik amaliyotga keng joriy etilishi aniq onkologiya (precision oncology) rivojlanishining muhim omili bo‘lib, kelajakda sun’iy intellekt va multi-omik texnologiyalar bilan uyg‘unlashgan holda sut bezi saratonini boshqarish samaradorligini yanada oshirishi kutilmoqda.

Kalit so‘zlar: sut bezi saratoni, yangi avlod sekvenslash, NGS, molekulyar diagnostika, genomika, maqsadli terapiya, BRCA1, BRCA2, PIK3CA, biomarkerlar, suyuq biopsiya, aniq onkologiya, irsiy saraton, mutatsiyalar, multi-omik tahlil.

First page

374

Last page

380

For citation:Kurbonova Z.Ch., Turobova M.Y., Eganberdiyev G’.M. - SUT BEZI SARATONIDA YANGI AVLOD SEKVENSLASH (NGS) TEKSHIRUVINING AFZALLIKLARI//New Day in Medicine 6(92)2026 374-380 https://newdayworldmedicine.com/en/new_day_medicine/6-92-2026

List of References

  1. Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173-180. doi:10.1001/jamaoncol.2018.4305.
  2. Amarasinghe SL, Su S, Dong X, Zappia L, Ritchie ME, Gouil Q. Opportunities and challenges in long-read sequencing data analysis. Genome Biol. 2020;21(1):30. doi:10.1186/s13059-020-1935-5.
  3. Aredo JV, Jamali A, Zhu J, Heater N, Wakelee HA, Vaklavas C, et al. Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring. Am Soc Clin Oncol Educ Book. 2025;45:e481114. doi:10.1200/EDBK_481114.
  4. Bizuayehu HM, Ahmed KY, Kibret GD, Dadi AF, Belachew SA, Bagade T, et al. Global disparities of cancer and its projected burden in 2050. JAMA Netw Open. 2024;7(11):e2443198. doi:10.1001/jamanetworkopen.2024.43198.
  5. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834.
  6. Chae YK, Oh MS. Detection of minimal residual disease using ctDNA in lung cancer: Current evidence and future directions. J Thorac Oncol. 2019;14:16-24.
  7. Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, et al. Somatic genomic testing in patients with metastatic or advanced cancer: ASCO provisional clinical opinion. J Clin Oncol. 2022;40(11):1231-1258. doi:10.1200/JCO.21.02767.
  8. Chou CY, Shen TT, Wang WC, Wu MP. Favorable breast cancer mortality-to-incidence ratios of countries with good human development index rankings and high health expenditures. Taiwan J Obstet Gynecol. 2024;63(4):527-531. doi:10.1016/j.tjog.2024.05.007.
  9. Diéras V, Han HS, Kaufman B, Wildiers H, Friedlander M, Ayoub JP, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(10):1269-1282. doi:10.1016/S1470-2045(20)30447-2.
  10. Eeckhoutte A, Houy A, Manié E, Reverdy M, Bièche I, Marangoni E, et al. ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing. Bioinformatics. 2020;36(12):3888-3889. doi:10.1093/bioinformatics/btaa393.

    file

    download